CY1122145T1 - Ανοσογονικη συνθεση για clostridium difficile - Google Patents
Ανοσογονικη συνθεση για clostridium difficileInfo
- Publication number
- CY1122145T1 CY1122145T1 CY20191101061T CY191101061T CY1122145T1 CY 1122145 T1 CY1122145 T1 CY 1122145T1 CY 20191101061 T CY20191101061 T CY 20191101061T CY 191101061 T CY191101061 T CY 191101061T CY 1122145 T1 CY1122145 T1 CY 1122145T1
- Authority
- CY
- Cyprus
- Prior art keywords
- clostridium difficile
- protein
- cdtb
- modify
- binding domain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000193163 Clostridioides difficile Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108010010925 Clostridium actin-specific ADP-ribosyltransferase Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411306.2A GB201411306D0 (en) | 2014-06-25 | 2014-06-25 | Immunogenic composition |
| GB201411371A GB201411371D0 (en) | 2014-06-26 | 2014-06-26 | Immunogenic composition |
| PCT/EP2015/064324 WO2015197737A1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122145T1 true CY1122145T1 (el) | 2020-11-25 |
Family
ID=53498986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101061T CY1122145T1 (el) | 2014-06-25 | 2019-10-09 | Ανοσογονικη συνθεση για clostridium difficile |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170218031A1 (enExample) |
| EP (2) | EP3160500B1 (enExample) |
| JP (2) | JP6688233B2 (enExample) |
| CN (1) | CN106536544B (enExample) |
| BE (1) | BE1022949B1 (enExample) |
| BR (1) | BR112016030096B1 (enExample) |
| CY (1) | CY1122145T1 (enExample) |
| DK (1) | DK3160500T3 (enExample) |
| ES (1) | ES2749701T3 (enExample) |
| HR (1) | HRP20191864T1 (enExample) |
| HU (1) | HUE045936T2 (enExample) |
| LT (1) | LT3160500T (enExample) |
| MX (1) | MX374380B (enExample) |
| PL (1) | PL3160500T3 (enExample) |
| PT (1) | PT3160500T (enExample) |
| SI (1) | SI3160500T1 (enExample) |
| WO (1) | WO2015197737A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201908376UA (en) | 2017-03-15 | 2019-10-30 | Novavax Inc | Methods and compositions for inducing immune responses against clostridium difficile |
| WO2019243307A1 (en) | 2018-06-19 | 2019-12-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| AU614755B2 (en) | 1987-06-05 | 1991-09-12 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Autocrine motility factors in cancer diagnosis and management |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ES2068989T3 (es) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoles como adyuvante en vacunas. |
| PT761231E (pt) | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
| SK117395A3 (en) | 1993-03-23 | 1996-11-06 | Smithkline Beecham Biolog | Vaccine composition and manufacturing process thereof |
| EP1041149B8 (en) | 1994-10-24 | 2007-10-03 | Allergan, Inc. | Vaccine and antitoxin for treatment and prevention of C. difficile disease |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP0832282A1 (en) | 1995-06-02 | 1998-04-01 | Incyte Pharmaceuticals, Inc. | IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES |
| WO2000061762A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE) |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| AU2003304316A1 (en) * | 2002-11-08 | 2005-01-28 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
| MX2014006630A (es) * | 2011-12-08 | 2014-07-09 | Novartis Ag | Vacuna a base toxina clostridium difficile. |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| AU2013354186A1 (en) * | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2015
- 2015-06-25 EP EP15733404.6A patent/EP3160500B1/en active Active
- 2015-06-25 PL PL15733404T patent/PL3160500T3/pl unknown
- 2015-06-25 ES ES15733404T patent/ES2749701T3/es active Active
- 2015-06-25 EP EP19192151.9A patent/EP3636278A3/en not_active Withdrawn
- 2015-06-25 HR HRP20191864TT patent/HRP20191864T1/hr unknown
- 2015-06-25 MX MX2016017094A patent/MX374380B/es active IP Right Grant
- 2015-06-25 LT LT15733404T patent/LT3160500T/lt unknown
- 2015-06-25 US US15/320,190 patent/US20170218031A1/en not_active Abandoned
- 2015-06-25 BR BR112016030096-3A patent/BR112016030096B1/pt active IP Right Grant
- 2015-06-25 JP JP2016575190A patent/JP6688233B2/ja active Active
- 2015-06-25 CN CN201580039744.7A patent/CN106536544B/zh active Active
- 2015-06-25 HU HUE15733404A patent/HUE045936T2/hu unknown
- 2015-06-25 SI SI201530954T patent/SI3160500T1/sl unknown
- 2015-06-25 WO PCT/EP2015/064324 patent/WO2015197737A1/en not_active Ceased
- 2015-06-25 BE BE2015/5390A patent/BE1022949B1/fr active
- 2015-06-25 PT PT157334046T patent/PT3160500T/pt unknown
- 2015-06-25 DK DK15733404T patent/DK3160500T3/da active
-
2019
- 2019-10-09 CY CY20191101061T patent/CY1122145T1/el unknown
-
2020
- 2020-01-17 JP JP2020005532A patent/JP2020100625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3160500T3 (pl) | 2020-02-28 |
| EP3636278A3 (en) | 2020-07-15 |
| DK3160500T3 (da) | 2019-11-11 |
| US20170218031A1 (en) | 2017-08-03 |
| MX2016017094A (es) | 2017-05-03 |
| ES2749701T3 (es) | 2020-03-23 |
| JP2017520573A (ja) | 2017-07-27 |
| HUE045936T2 (hu) | 2020-01-28 |
| PT3160500T (pt) | 2019-11-11 |
| BR112016030096A2 (pt) | 2017-08-22 |
| CN106536544B (zh) | 2020-04-07 |
| CA2952118A1 (en) | 2015-12-30 |
| EP3636278A2 (en) | 2020-04-15 |
| JP2020100625A (ja) | 2020-07-02 |
| EP3160500A1 (en) | 2017-05-03 |
| JP6688233B2 (ja) | 2020-04-28 |
| SI3160500T1 (sl) | 2019-11-29 |
| BE1022949B1 (fr) | 2016-10-21 |
| BR112016030096A8 (pt) | 2021-07-06 |
| LT3160500T (lt) | 2019-10-25 |
| BR112016030096B1 (pt) | 2023-10-03 |
| BE1022949A1 (fr) | 2016-10-21 |
| CN106536544A (zh) | 2017-03-22 |
| HRP20191864T1 (hr) | 2020-01-10 |
| EP3160500B1 (en) | 2019-08-21 |
| MX374380B (es) | 2025-03-06 |
| WO2015197737A1 (en) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| DOP2021000022A (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
| CY1122898T1 (el) | Απεκκριση πολυπεπτιδιων που περιεχουν αιμη | |
| CO2018011804A2 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos | |
| CY1124979T1 (el) | Κατασκευασματα πρωτεϊνης uspa2 και χρησεις αυτων | |
| MX2022005202A (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. | |
| BR112018005779A2 (pt) | repressores de htt e usos dos mesmos | |
| IL263846B (en) | Formulation of a peptide vaccine | |
| BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| MX2017008191A (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6. | |
| CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
| MX371033B (es) | Productos farmacéuticos mejorados de péptido para resistencia a la insulina. | |
| EA201692002A1 (ru) | Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство | |
| SV2016005352A (es) | Anticuerpos antagonistas del interferon alfa y omega | |
| DK3199179T3 (da) | Formulering af rekombinant fusionsprotein | |
| CY1124727T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| BR112015025748A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna | |
| MX377774B (es) | Formulaciones de proteinas. | |
| CY1122145T1 (el) | Ανοσογονικη συνθεση για clostridium difficile | |
| CL2017001310A1 (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis | |
| EP3534944A4 (en) | COMBINATION OF A LISTERIA-BASED VACCINE WITH ANTI-CTLA-4 OR ANTI-CD137 ANTIBODIES | |
| EP3475418A4 (en) | TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND THEIR USE | |
| EA202091567A1 (ru) | Химерные белки мти |